Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia: Initial response and relationship to multidrug resistance gene 1
✍ Scribed by Wells, Robert J. ;Odom, Lorrie F. ;Gold, Stuart H. ;Feusner, James ;Krill, Carl E. ;Waldron, Peter ;Moulton, Thomas A. ;Knoppell, Eva ;White, Michael L ;Cairo, Mitchell S.
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 617 KB
- Volume
- 22
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The objective of this study was to determine the response rate and toxicity of high‐dose cytosine arabinoside (AC) and mitoxantrone (M) in relapsed or refractory childhood acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) and to correlate response with the expression of the multidrug resistance gene 1 (mdr1). Twenty‐nine patients were treated with AC 1.0 g/m^2^ infused over 2 h every 12 h for eight doses (days 1‐4) and M 12 mg/m^2^ infused over 1 h (days 3‐6). Mdr1 expression was determined by a polymerase chain reaction (per) assay. Ten of 15 patients (67%) with AML obtained a complete remission (CR) of 3 to 30+ months duration. Eight of 14 (57%) ALL patients obtained a CR of 1 to 23+ months duration. The major toxicities were hematopoietic and infectious. Seventy‐nine per cent of patients developed a documented infection during induction. Mdr1 did not correlate with a lower induction rate. This AC/M regimen is active in childhood AML and ALL. © 1994 Wiley‐Liss, Inc.